What was the market valuation of the US cystic fibrosis market in 2024?

The market valuation of the US cystic fibrosis market was $1436.4 Million in 2024. Read More

What is the projected market valuation for the US cystic fibrosis market by 2035?

The projected market valuation for the US cystic fibrosis market is $5484.15 Million by 2035. Read More

What is the expected CAGR for the US cystic fibrosis market during the forecast period 2025 - 2035?

The expected CAGR for the US cystic fibrosis market during the forecast period 2025 - 2035 is 12.95%. Read More

Which companies are considered key players in the US cystic fibrosis market?

Key players in the US cystic fibrosis market include Vertex Pharmaceuticals, AbbVie, Gilead Sciences, Novartis, Teva Pharmaceutical Industries, Chiesi Farmaceutici, MediGene, and Eloxx Pharmaceuticals. Read More

What were the treatment method segment valuations in the US cystic fibrosis market?

In the treatment method segment, the valuations were $1000.0 Million for medication and $436.4 Million for devices. Read More

How does the route of administration segment perform in the US cystic fibrosis market?

The route of administration segment had valuations of $600.0 Million for oral and $836.4 Million for inhaled treatments. Read More

What are the valuations for different drug classes in the US cystic fibrosis market?

The drug class segment included valuations of $300.0 Million for pancreatic enzyme supplements, $250.0 Million for mucolytics, $200.0 Million for bronchodilators, $250.0 Million for antibiotics, and $436.4 Million for CFTR modulators. Read More

What is the significance of CFTR modulators in the US cystic fibrosis market?

CFTR modulators represent a substantial valuation of $436.4 Million in the drug class segment, indicating their critical role in treatment. Read More

How do the device segment valuations compare to medication in the US cystic fibrosis market?

The device segment valuation of $436.4 Million is considerably lower than the medication segment valuation of $1000.0 Million. Read More

What trends are anticipated for the US cystic fibrosis market in the coming years?

Trends suggest that the US cystic fibrosis market will experience robust growth, potentially reaching $5484.15 Million by 2035. Read More

US Cystic Fibrosis Market

ID: MRFR/Pharma/16502-CR

100 Pages

Nidhi Mandole

Last Updated: January 29, 2026

US Cystic Fibrosis Market Research Report: Size, Share, Trend Analysis By Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, Antibiotics, CFTR modulators) By Treatment Method (Medication, Devices) By Route of Administration (Oral, Inhaled) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Security, Access Control and Robotics, BY Treatment Method (USD Million)
  1. 4.1.1 Medication
  2. 4.1.2 Devices
2. 4.2 Security, Access Control and Robotics, BY Route of Administration (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Inhaled
3. 4.3 Security, Access Control and Robotics, BY Drug Class (USD Million)
  1. 4.3.1 Pancreatic Enzyme Supplements
  2. 4.3.2 Mucolytic
  3. 4.3.3 Bronchodilators
  4. 4.3.4 Antibiotics
  5. 4.3.5 CFTR modulators
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Vertex Pharmaceuticals (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 AbbVie (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Gilead Sciences (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Teva Pharmaceutical Industries (IL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Chiesi Farmaceutici (IT)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 MediGene (DE)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eloxx Pharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT METHOD
3. 6.3 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 US MARKET ANALYSIS BY DRUG CLASS
5. 6.5 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
8. 6.8 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
10. 6.10 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
11. 6.11 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT METHOD, 2024 (% SHARE)
12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY TREATMENT METHOD, 2024 TO 2035 (USD Million)
13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG CLASS, 2024 (% SHARE)
16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT METHOD, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DRUG CLASS, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Security, Access Control and Robotics Market Segmentation

Security, Access Control and Robotics By Treatment Method (USD Million, 2025-2035)

Medication
Devices

Security, Access Control and Robotics By Route of Administration (USD Million, 2025-2035)

Oral
Inhaled

Security, Access Control and Robotics By Drug Class (USD Million, 2025-2035)

Pancreatic Enzyme Supplements
Mucolytic
Bronchodilators
Antibiotics
CFTR modulators

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”